Earendil Labs
PrivateLast Round
Series B
Mar 20, 2026
Total Funding Raised
$861.8M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Earendil Labs is a biotechnology company that develops an AI-driven platform for biologics discovery and development to treat autoimmune diseases and cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Medical AI, ML Platforms
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share, Subscription SaaS
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Earendil Labs Comparables
Compare Earendil Labs with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| BigHat Biosciences | 87% | |
| LabGenius Therapeutics | 82% | |
| Alphabet Inc. | 81% |
For institutional investors. Book with your work email.
Earendil Labs Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Mar 20, 2026 | ||||
| Series A | Jun 22, 2022 |
For institutional investors. Book with your work email.
Earendil Labs Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| DST Global | Series B |
| Hillhouse Investment | Series A, Series B |
| Dimension | Series B |
| 渶策资本 | Series B |
| 5Y Capital | Series A |
| Luminous Ventures | Series B |
| Dimensional Fund Advisors | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 2, 2026
Partnered with Helixon Therapeutics to advance therapeutic programs using AI.
- Mar 20, 2026
$787M round led by Dimensional Fund Advisors and Sanofi.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingSep 25, 2026
Earendil is building an AI-driven high-throughput biology platform with Genentech that integrates AI into biologics research and development through predictive protein modeling, generative protein design, and rapid experimental validation on Sep 25th '26.
- partners_withSep 25, 2026
Earendil partnered with Novo Nordisk A/S on Sep 21st '26.
- licenses_technologySep 25, 2026
Earendil licenses two bispecific antibodies to Sanofi for autoimmune conditions and inflammatory bowel diseases in Apr '25 in a deal that includes a $125 million payment and up to $1.72 billion in milestones.
- is_developingSep 25, 2026
On Sep 24th '26 in Delaware, Earendil announced a research collaboration with Genentech to discover and develop multiple therapeutic bispecific antibody programs in oncology.
- partners_withSep 25, 2026
Earendil and Genentech, Inc. enter a platform deal in Sep '26 to discover and develop multiple oncology bispecific antibody therapies, with $55 million upfront and potential payments exceeding $1.5 billion.
For institutional investors. Book with your work email.
Earendil Labs Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Earendil Labs's valuation, stock price, and market status.
Is Earendil Labs a public or private company?
Earendil Labs is a private company.
What is the current stock price of Earendil Labs?
Earendil Labs is a private company, so its shares have no public market price. Caplight tracks Earendil Labs's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Earendil Labs worth (valuation)?
Valuation information for Earendil Labs is not publicly available.
Can I buy Earendil Labs stock?
Earendil Labs shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Earendil Labs's last funding round?
Earendil Labs's most recent funding round was Series B on March 20, 2026.
Who are the main investors in Earendil Labs?
Key investors in Earendil Labs include DST Global, Dimension, 5Y Capital, Dimensional Fund Advisors.
Will Earendil Labs IPO soon?
No public IPO plans have been announced for Earendil Labs.
How can I track Earendil Labs secondary market activity?
Caplight tracks bids, offers, and trades in Earendil Labs's shares on secondary markets.